Lym-1 and lym-2 targeted car cell immunotherapy
AssigneeUniversity of Southern California
InventorAlan L. Epstein
Life of this patent
Estimating the term…
Abstract
CAR cells targeting and antibodies human HLA-DR are described as a new method of cancer treatment. It is proposed that HLA-DR CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-DR.
Claims29
A chimeric antigen receptor (CAR) comprising:
- (a) an antigen binding domain of an anti-HLA-DR antibody;
- (b) a CD8 α hinge domain;
- (c) a CD8 α transmembrane domain;
- (d) a CD28 costimulatory signaling region and/or a 4-1BB costimulatory signaling region;
- and (e) a CD3 zeta signaling domain.
3-10. (canceled)
13-14. (canceled)
16-17. (canceled)
19-20. (canceled)
A method of producing HLA-DR CAR expressing cells comprising:
- (i) transducing a population of isolated cells with a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising:
- (a) an antigen binding domain of an anti-HLA-DR antibody;
- (b) a CD8 α hinge domain;
- (c) a CD8 α transmembrane domain;
- (d) a CD28 costimulatory signaling region and/or a 4-1BB costimulatory signaling region;
- and (e) a CD3 zeta signaling domain;
- and
- (ii) selecting a subpopulation of said isolated cells that have been successfully transduced with said nucleic acid sequence of step (i) thereby producing HLA-DR CAR expressing cells.
27-30. (canceled)
32-37. (canceled)
A method for determining if a subject is likely to respond or is not likely to HLA-DR CAR therapy, comprising:
- (i) contacting a tumor or cancer sample isolated from the patient with an agent that selectively binds HLA-DR, wherein the presence of the agent bound to the tumor or cancer sample indicates that the subject is likely to respond to the HLA-DR CAR therapy and the absence of the agent bound to the tumor or cancer sample indicates that the subject is not likely to respond to the HLA-DR CAR therapy;
- and/or
- (ii) determining the expression level of HLA-DR polypeptide in a tumor or cancer sample isolated from the subject, wherein an elevated expression of the HLA-DR polypeptide as compared to a normal, counterpart sample indicates that the subject is likely to respond to the HLA-DR CAR therapy and lack of elevated expression indicates that the subject is not likely to respond to the HLA-DR therapy.
40-42. (canceled)
A method for monitoring HLA-DR CAR therapy in a subject receiving the therapy, comprising contacting a sample isolated from the patient with an agent that selectively binds HLA-DR and determining the presence of any agent bound to the sample.
45-47. (canceled)
(canceled)
A kit comprising an HLA-DR CAR therapy and instructions for use.
Dependencies are inferred from the claim text.